Company news

Molecular Partners AG news in 2026

Molecular Partners AG's news releases, calls and decks from 2026, newest first.

View company

Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026

November 5, 2026

Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy

October 29, 2026

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

August 25, 2026

Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma

July 16, 2026

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

July 15, 2026

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

July 6, 2026

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

July 2, 2026

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

May 30, 2026

Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

May 26, 2026

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

May 12, 2026

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences

May 4, 2026

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

May 1, 2026

Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712

April 19, 2026

Molecular Partners statement regarding Passive Foreign Investment Company status

April 16, 2026

Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting

April 14, 2026

Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors

March 23, 2026

Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes

March 19, 2026

Molecular Partners to Hold Three Poster Presentations at AACR 2026

March 17, 2026

Molecular Partners Reports Highlights and Financial Results for Full Year 2025

March 12, 2026

Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics

February 26, 2026

Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results

February 26, 2026

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

February 2, 2026

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference

January 11, 2026

Decks in 2026